Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      Context: Diabetic kidney disease (DKD) affects nearly 40% of diabetic patients, often leading to end-stage renal disease that requires renal replacement therapies, such as dialysis and transplantation. the gut microbiota, an integral aspect of human evolution, plays a crucial role in this condition. Traditional chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota. Objective: this review elucidates the modifications in gut microbiota observed in DKD and explores the impact of TCM interventions on correcting microbial dysregulation. Methods: we searched relevant articles from databases including web of Science, PubMed, ScienceDirect, wiley, and Springer Nature. the following keywords were used: diabetic kidney disease, diabetic nephropathy, gut microbiota, natural product, TCM, chinese herbal medicine, and chinese medicinal herbs. Rigorous criteria were applied to identify high-quality studies on tcM interventions against DKD. Results: Dysregulation of the gut microbiota, including Lactobacillus, Streptococcus, and Clostridium, has been observed in individuals with DKD. Key indicators of microbial dysregulation include increased uremic solutes and decreased short-chain fatty acids. various TCM therapies, such as formulas, tablets, granules, capsules, and decoctions, exhibit unique advantages in regulating the disordered microbiota to treat DKD. Conclusion: this review highlights the importance of targeting the gut-kidney axis to regulate microbial disorders, their metabolites, and associated signaling pathways in DKD. The Qing-Re-Xiao-Zheng formula, the Shenyan Kangfu tablet, the Huangkui capsule, and the Bekhogainsam decoction are potential candidates to address the gut-kidney axis. TCM interventions offer a significant therapeutic approach by targeting microbial dysregulation in patients with DKD. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Pharmaceutical Biology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)